Article Text

Download PDFPDF

P2.120 Incidence and Risk Factors of Herpes Zoster Among HIV-Positive Patients in the Cohort of the German Competence Network For HIV/AIDS (KompNet)
  1. C Michalik1,2,
  2. K Jansen1,3,
  3. B Haastert4,
  4. S Dupke1,5,
  5. S Esser1,6,
  6. A Plettenberg1,7,
  7. S Köppe1,8,
  8. A Guignard9,
  9. A Skaletz-Rorowski1,3,
  10. N H Brockmeyer1,3,10
  1. 1Competence Network for HIV/AIDS, Ruhr-Universität Bochum, Bochum, Germany
  2. 2Centre for Clinical Trials, Cologne, Germany
  3. 3Clinic for Dermatology, Venerology and Allergology, Ruhr-Universität Bochum, Bochum, Germany
  4. 4mediStatistica, Neuenrade, Germany
  5. 5Private practise Driesener Strasse, Berlin, Germany
  6. 6Clinic for Dermatology and Venerology, University Clinic, Essen, Germany
  7. 7Ifi-Institute, Asklepios-Clinic, Hamburg, Germany
  8. 8Medical Practice Mehringdamm, Berlin, Germany
  9. 9GSK Biologicals, Wavre, Belgium
  10. 10German STI-Society (DSTIG), Bochum, Germany


Background HIV infection is a risk factor for development of Herpes Zoster (HZ) and its complications. There is limited evidence on the impact of antiretroviral therapy (ART) on the occurrence of HZ among HIV-infected adults.

Methods Study population was drawn from the KompNet HIV cohort. Inclusion criteria were: age ≥ 18 years, record of HIV diagnosis date (t0), record of CD4 count available ± 6 months from t0. Patients without month of HZ diagnoses were excluded. Study period was 1.1.1985–1.7.2010.

Incidences of all HZ events were estimated assuming Poisson distribution, uni-/multivariate Cox proportional Hazard ratio (HR) regression models were fitted to identify risk factors for a first HZ event. Independent variables were: sex, age at HIV diagnosis, HIV transmission route, ART status, CD4-value before HZ episode, immunosuppressive medication, mode of data documentation (retrospective/prospective).

Results Study population comprised 3,757 subjects (86% male, 66% MSM, 3% IVDU, 92% Caucasian), mean age at HIV diagnosis was 38 years, mean observation time was 5.8 years.

362 HZ events were recorded in 326 patients (8.6%), resulting in an HZ incidence of 16.7/1,000 PY overall and 16.1/1,000 PY for first HZ cases. Main risk factors associated with first HZ event were: no ART compared to an ART containing a non-nucleoside reverse-transcriptase inhibitor (NNRTI vs no ART; HR 0.530, p < 0.001) or a protease inhibitor (PI vs no ART; HR 0.624, p = 0.004), lower CD4-cell count (rise 100 cells/μl, HR 0.918, p = 0.001) and retrospective data documentation (HR 0.582, p < 0.001). No risk factors were: sex, age, HIV transmission route, immunosuppressive medication.

Conclusions According to former studies incidence of HZ in HIV-infected individuals was ∼5 times higher than in the general population. Our study showed ART as important protective associated factor for HZ events. Reasons may be earlier HIV-diagnosis, more recent picturing of ART, and low IVDU proportion in our study.

  • cohort
  • Herpes zoster
  • HIV KL01,

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.